Olszewski Recaps Results of Mosunetuzumab in Elderly/Unfit DLBCL

Adam J. Olszewski, MD, associate professor of medicine at Brown University, lymphoma clinician at Rhode Island Hospital in Providence, Rhode Island, discusses the promising results of a phase 1b/2 study (NCT03677154) of mosunetuzumab (Lunsumio) for the treatment of elderly/unfit patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

According to findings from the study, treatment with mosunetuzumab was effective and induced durable complete responses (CR) in this patient population. A total of 43% of patients achieved a CR and a median duration of response of 15.8 months.

Additionally, 38% of patients were alive and did not have any evidence of disease after 1 year of follow-up. Overall, these results suggest that mosunetuzumab may be an effective treatment option for elderly/unfit patients with DLBCL who are not candidates for standard chemotherapy.

Transcription:

0:10 | These responses are built to be durable. Right now, the median duration of complete response is up to 3 years, and we will find out if these patients ever experienced a relapse. So far out of 23 patients who had a complete response only 3 experienced relapse. The other 20 are continuing with complete responses.

0:28 | Out of 54 patients, 20 elderly patients in my practice and at other practices from investigators who participated in this trial live without any evidence of lymphoma. Some [patients] have passed away from natural causes because it is an elderly population. We have faced challenges related to the COVID pandemic. Mosunetuzumab is a B-cell depleting therapy, which can increase the risk of serious COVID complications, but we have learned how to manage it, especially using the prophylactic measures and available treatments. So altogether, a year after starting this therapy, 3 quarters of these patients were alive, and about 38% of patients were alive without any evidence of disease.